CMOPF Quote, Financials, Valuation and Earnings

GH Research Plc has a net margin of -- compared to Cosmo Pharmaceuticals NV's net margin of --. Cosmo Pharmaceuticals NV's return on equity of 15.06% beat GH Research Plc's return on equity of -17.7%.

Cosmo Pharmaceuticals NV has a consensus price target of --, signalling downside risk potential of --. On the other hand GH Research Plc has an analysts' consensus of $39.25 which suggests that it could grow by 169.39%. Given that GH Research Plc has higher upside potential than Cosmo Pharmaceuticals NV, analysts believe GH Research Plc is more attractive than Cosmo Pharmaceuticals NV.

Cosmo Pharmaceuticals NV has a beta of 0.580, which suggesting that the stock is 41.965% less volatile than S&P 500. In comparison GH Research Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cosmo Pharmaceuticals NV has a quarterly dividend of $2.34 per share corresponding to a yield of 4.14%. GH Research Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmo Pharmaceuticals NV pays 24.72% of its earnings as a dividend. GH Research Plc pays out -- of its earnings as a dividend. Cosmo Pharmaceuticals NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cosmo Pharmaceuticals NV quarterly revenues are --, which are smaller than GH Research Plc quarterly revenues of --. Cosmo Pharmaceuticals NV's net income of -- is lower than GH Research Plc's net income of -$14.1M. Notably, Cosmo Pharmaceuticals NV's price-to-earnings ratio is 38.26x while GH Research Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmo Pharmaceuticals NV is 14.79x versus -- for GH Research Plc. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of -- compared to Cosmo Pharmaceuticals NV's net margin of 16.98%. Cosmo Pharmaceuticals NV's return on equity of 15.06% beat Jazz Pharmaceuticals Plc's return on equity of -8.79%.

Cosmo Pharmaceuticals NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $223.50 which suggests that it could grow by 19.55%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Cosmo Pharmaceuticals NV, analysts believe Jazz Pharmaceuticals Plc is more attractive than Cosmo Pharmaceuticals NV.

Cosmo Pharmaceuticals NV has a beta of 0.580, which suggesting that the stock is 41.965% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.231, suggesting its less volatile than the S&P 500 by 76.921%.

Cosmo Pharmaceuticals NV has a quarterly dividend of $2.34 per share corresponding to a yield of 4.14%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmo Pharmaceuticals NV pays 24.72% of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend. Cosmo Pharmaceuticals NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cosmo Pharmaceuticals NV quarterly revenues are --, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.2B. Cosmo Pharmaceuticals NV's net income of -- is lower than Jazz Pharmaceuticals Plc's net income of $203.5M. Notably, Cosmo Pharmaceuticals NV's price-to-earnings ratio is 38.26x while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmo Pharmaceuticals NV is 14.79x versus 2.69x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Prothena Corp. Plc has a net margin of -- compared to Cosmo Pharmaceuticals NV's net margin of -102804.76%. Cosmo Pharmaceuticals NV's return on equity of 15.06% beat Prothena Corp. Plc's return on equity of -66.9%.

Cosmo Pharmaceuticals NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Prothena Corp. Plc has an analysts' consensus of $21.00 which suggests that it could grow by 112.98%. Given that Prothena Corp. Plc has higher upside potential than Cosmo Pharmaceuticals NV, analysts believe Prothena Corp. Plc is more attractive than Cosmo Pharmaceuticals NV.

Cosmo Pharmaceuticals NV has a beta of 0.580, which suggesting that the stock is 41.965% less volatile than S&P 500. In comparison Prothena Corp. Plc has a beta of -0.328, suggesting its less volatile than the S&P 500 by 132.825%.

Cosmo Pharmaceuticals NV has a quarterly dividend of $2.34 per share corresponding to a yield of 4.14%. Prothena Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmo Pharmaceuticals NV pays 24.72% of its earnings as a dividend. Prothena Corp. Plc pays out -- of its earnings as a dividend. Cosmo Pharmaceuticals NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cosmo Pharmaceuticals NV quarterly revenues are --, which are smaller than Prothena Corp. Plc quarterly revenues of $21K. Cosmo Pharmaceuticals NV's net income of -- is lower than Prothena Corp. Plc's net income of -$21.6M. Notably, Cosmo Pharmaceuticals NV's price-to-earnings ratio is 38.26x while Prothena Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmo Pharmaceuticals NV is 14.79x versus 53.93x for Prothena Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.